Strategic Biopharma Transactions: Bispecific Antibodies, Targeted Radioligands, and Genomic RNA Platforms

GSK (LSE: GSK) entered an exclusive in-licensing agreement with Chimagen Biosciences valued at $300 million upfront cash, with up to $550 million in contingent development and commercial success milestones — an $850M total package. The asset is CMG1A4, a Phase I clinical-stage dual CD19/CD20 T-cell engager (TCE) monoclonal antibody targeting systemic lupus erythematosus (SLE) and lupus nephritis.

Strategically, the deal strengthens GSK's clinical immunology portfolio alongside Benlysta by acquiring a targeted B-cell depletion biologic with potential for deep tissue reset. The market impact accelerates the competitive race among Big Pharma players to transition dual-targeted TCE biologics from oncology into refractory autoimmune indications.

BioNTech (Nasdaq: BNTX) executed a definitive M&A acquisition of Biotheus for $800 million upfront cash payment, plus up to $150 million in clinical and commercial regulatory milestones — a $950M total enterprise value. The acquired asset is BNT327/PM8002, a Phase II/III clinical-stage bispecific antibody targeting PD-L1 and VEGF-A across multiple solid tumor malignancies.

The transaction secures full global rights to a foundational immuno-oncology asset to anchor BioNTech's clinical combination therapies with mRNA cancer vaccines. It establishes BioNTech as a major competitor against Ivonescimab (AK112) in the emerging dual immune-checkpoint/anti-angiogenic bispecific antibody paradigm.

Eli Lilly and Company (NYSE: LLY) formed a co-development and option-to-license alliance with HAYA Therapeutics, contributing $100 million in upfront equity investment and technology access fees, with up to $1.0 billion in aggregate research, development, and sales milestones. The platform is a preclinical lncRNA genome-mapping engine (miR-PREDICT) targeting regulatory long non-coding RNA candidates for metabolic conditions and obesity.

The rationale expands Lilly's obesity discovery efforts beyond peptide agonists toward tissue-specific RNA-based genomic regulatory mechanisms. The deal validates long non-coding RNA (lncRNA) targets as viable drug discovery engines for cardiometabolic disease interventions.

Sanofi (Nasdaq: SNY) secured an exclusive out-licensing and asset acquisition with RadioMedix for $110 million upfront payment, up to $330 million in development and commercial milestones, plus tiered single-to-double-digit royalties. The asset is AlphaMedix (Lead-212 / 212Pb-DOTAMTATE), a Phase II targeted alpha-therapy (TAT) radiopharmaceutical for somatostatin receptor-positive neuroendocrine tumors (NETs).

The deal deepens Sanofi's commitment to precision oncology by securing a late-stage targeted radioligand program with FDA Fast Track designation. The market impact escalates Big Pharma competition in alpha-emitting radiopharmaceuticals, challenging incumbent beta-emitters like Lutathera in rare GI neuroendocrine cancers.

AstraZeneca (Nasdaq: AZN) entered an out-licensing and option agreement with CSPC Pharmaceutical Group for $100 million upfront consideration, with up to $1.92 billion in contingent clinical, regulatory, and commercial milestone payments. The asset is YS-201 (AZD0780), a Phase I oral small-molecule PCSK9 inhibitor for hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD).

The transaction complements AstraZeneca's dyslipidemia and cardiovascular portfolio with a patient-friendly oral small molecule alternative to injectable monoclonal antibodies. It heightens pressure on oral PCSK9 developers by pairing a high-potency candidate with AstraZeneca's global cardiometabolic trial infrastructure.